Literature DB >> 22690822

Nonamorphism in flufenamic acid and a new record for a polymorphic compound with solved structures.

Vilmalí López-Mejías1, Jeff W Kampf, Adam J Matzger.   

Abstract

The unprecedented polymorphism of the non-steroidal anti-inflammatory drug (NSAID) flufenamic acid (FFA) is described here. Nine polymorphs were accessed through the use of polymer-induced heteronucleation (PIHn) and solid-solid transformation at low temperature. Structural elucidation of six of these forms, in addition to the two previously known forms, makes FFA indisputably octamorphic. Although the structure of at least one other form of FFA remains elusive, the occurrence of most of these polymorphs under one crystallization condition through PIHn illustrates that a fine interplay exists among the kinetic factors that lead to phase selection in this NSAID.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22690822      PMCID: PMC3634867          DOI: 10.1021/ja302601f

Source DB:  PubMed          Journal:  J Am Chem Soc        ISSN: 0002-7863            Impact factor:   15.419


  18 in total

1.  The use of polymer heteronuclei for crystalline polymorph selection.

Authors:  Meidong Lang; Adam L Grzesiak; Adam J Matzger
Journal:  J Am Chem Soc       Date:  2002-12-18       Impact factor: 15.419

2.  Abundant polymorphism in a system with multiple hydrogen-bonding opportunities: oxalyl dihydrazide.

Authors:  Shinbyoung Ahn; Fang Guo; Benson M Kariuki; Kenneth D M Harris
Journal:  J Am Chem Soc       Date:  2006-07-05       Impact factor: 15.419

3.  Infrared identification of pharmaceutically important sulphonamides with particular reference to the occurrence of polymorphism.

Authors:  R J Mesley; E E Houghton
Journal:  J Pharm Pharmacol       Date:  1967-05       Impact factor: 3.765

4.  Infrared identification of barbiturates with particular reference to the occurrence of polymorphism.

Authors:  R J Mesley; R L Clements
Journal:  J Pharm Pharmacol       Date:  1968-05       Impact factor: 3.765

5.  [Polymorphism of barbiturates caused by solvents].

Authors:  K Nikolics; G Bidló; K Nikolics
Journal:  Acta Pharm Hung       Date:  1974-05

6.  Crystalline polymorph selection and discovery with polymer heteronuclei.

Authors:  Christopher P Price; Adam L Grzesiak; Adam J Matzger
Journal:  J Am Chem Soc       Date:  2005-04-20       Impact factor: 15.419

7.  Crystal polymorphism in a carbamazepine derivative: oxcarbazepine.

Authors:  Katie M Lutker; Adam J Matzger
Journal:  J Pharm Sci       Date:  2010-02       Impact factor: 3.534

8.  Structural studies of analgesics and their interactions. XII. Structure and interactions of anti-inflammatory fenamates. A concerted crystallographic and theoretical conformational study.

Authors:  V Dhanaraj; M Vijayan
Journal:  Acta Crystallogr B       Date:  1988-08-01

9.  A new gamma-polymorph of chlorpropamide: 4-chloro-N-(propylaminocarbonyl)benzenesulfonamide.

Authors:  Tatiana N Drebushchak; Nikita V Chukanov; Elena V Boldyreva
Journal:  Acta Crystallogr C       Date:  2007-05-11       Impact factor: 1.172

10.  Investigation of a Privileged Polymorphic Motif: a Dimeric ROY Derivative.

Authors:  Katie M Lutker; Zachary P Tolstyka; Adam J Matzger
Journal:  Cryst Growth Des       Date:  2008       Impact factor: 4.076

View more
  18 in total

1.  Polymorphism in phenobarbital: discovery of a new polymorph and crystal structure of elusive form V.

Authors:  Saikat Roy; N Rajesh Goud; Adam J Matzger
Journal:  Chem Commun (Camb)       Date:  2016-03-21       Impact factor: 6.222

2.  The Bioenhancer Piperine is at Least Trimorphic.

Authors:  Laura Y Pfund; Brianna L Chamberlin; Adam J Matzger
Journal:  Cryst Growth Des       Date:  2015-03-23       Impact factor: 4.076

Review 3.  Flufenamic acid as an ion channel modulator.

Authors:  Romain Guinamard; Christophe Simard; Christopher Del Negro
Journal:  Pharmacol Ther       Date:  2013-01-25       Impact factor: 12.310

4.  Revealing Polymorphic Phase Transformations in Polymer-Based Hot Melt Extrusion Processes.

Authors:  José R Hernández Espinell; Vilmalí López-Mejías; Torsten Stelzer
Journal:  Cryst Growth Des       Date:  2018-03-09       Impact factor: 4.076

5.  Controlling pharmaceutical crystallization with designed polymeric heteronuclei.

Authors:  Laura Y Pfund; Christopher P Price; Jessica J Frick; Adam J Matzger
Journal:  J Am Chem Soc       Date:  2015-01-06       Impact factor: 15.419

6.  Disappearing polymorphs revisited.

Authors:  Dejan-Krešimir Bučar; Robert W Lancaster; Joel Bernstein
Journal:  Angew Chem Int Ed Engl       Date:  2015-06-08       Impact factor: 15.336

7.  Combinatorial selection of molecular conformations and supramolecular synthons in quercetin cocrystal landscapes: a route to ternary solids.

Authors:  Ritesh Dubey; Gautam R Desiraju
Journal:  IUCrJ       Date:  2015-06-11       Impact factor: 4.769

8.  The Crystal Structure and Intermolecular Interactions in Fenamic Acids-Acridine Complexes.

Authors:  Marta S Krawczyk; Adam Sroka; Irena Majerz
Journal:  Molecules       Date:  2021-05-16       Impact factor: 4.411

9.  Towards exhaustive and automated high-throughput screening for crystalline polymorphs.

Authors:  Laura Y Pfund; Adam J Matzger
Journal:  ACS Comb Sci       Date:  2014-06-20       Impact factor: 3.784

Review 10.  Can computed crystal energy landscapes help understand pharmaceutical solids?

Authors:  Sarah L Price; Doris E Braun; Susan M Reutzel-Edens
Journal:  Chem Commun (Camb)       Date:  2016-04-12       Impact factor: 6.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.